209 related articles for article (PubMed ID: 35350066)
1. Suppression of Endothelial Cell FAK Expression Reduces Pancreatic Ductal Adenocarcinoma Metastasis after Gemcitabine Treatment.
Roy-Luzarraga M; Reynolds LE; de Luxán-Delgado B; Maiques O; Wisniewski L; Newport E; Rajeeve V; Drake RJG; Gómez-Escudero J; Richards FM; Weller C; Dormann C; Meng YM; Vermeulen PB; Saur D; Sanz-Moreno V; Wong PP; Géraud C; Cutillas PR; Hodivala-Dilke K
Cancer Res; 2022 May; 82(10):1909-1925. PubMed ID: 35350066
[TBL] [Abstract][Full Text] [Related]
2. The extracellular matrix and focal adhesion kinase signaling regulate cancer stem cell function in pancreatic ductal adenocarcinoma.
Begum A; Ewachiw T; Jung C; Huang A; Norberg KJ; Marchionni L; McMillan R; Penchev V; Rajeshkumar NV; Maitra A; Wood L; Wang C; Wolfgang C; DeJesus-Acosta A; Laheru D; Shapiro IM; Padval M; Pachter JA; Weaver DT; Rasheed ZA; Matsui W
PLoS One; 2017; 12(7):e0180181. PubMed ID: 28692661
[TBL] [Abstract][Full Text] [Related]
3. Increased expression of tissue transglutaminase in pancreatic ductal adenocarcinoma and its implications in drug resistance and metastasis.
Verma A; Wang H; Manavathi B; Fok JY; Mann AP; Kumar R; Mehta K
Cancer Res; 2006 Nov; 66(21):10525-33. PubMed ID: 17079475
[TBL] [Abstract][Full Text] [Related]
4. The FAK scaffold inhibitor C4 disrupts FAK-VEGFR-3 signaling and inhibits pancreatic cancer growth.
Kurenova E; Liao J; He DH; Hunt D; Yemma M; Bshara W; Seshadri M; Cance WG
Oncotarget; 2013 Oct; 4(10):1632-46. PubMed ID: 24142503
[TBL] [Abstract][Full Text] [Related]
5. Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy.
Jiang H; Hegde S; Knolhoff BL; Zhu Y; Herndon JM; Meyer MA; Nywening TM; Hawkins WG; Shapiro IM; Weaver DT; Pachter JA; Wang-Gillam A; DeNardo DG
Nat Med; 2016 Aug; 22(8):851-60. PubMed ID: 27376576
[TBL] [Abstract][Full Text] [Related]
6. Exploring the therapeutic potential of focal adhesion kinase inhibition in overcoming chemoresistance in pancreatic ductal adenocarcinoma.
Scianò F; Terrana F; Pecoraro C; Parrino B; Cascioferro S; Diana P; Giovannetti E; Carbone D
Future Med Chem; 2024 Feb; 16(3):271-289. PubMed ID: 38269431
[TBL] [Abstract][Full Text] [Related]
7. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S
Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
[TBL] [Abstract][Full Text] [Related]
8. Development of resistance to FAK inhibition in pancreatic cancer is linked to stromal depletion.
Jiang H; Liu X; Knolhoff BL; Hegde S; Lee KB; Jiang H; Fields RC; Pachter JA; Lim KH; DeNardo DG
Gut; 2020 Jan; 69(1):122-132. PubMed ID: 31076405
[TBL] [Abstract][Full Text] [Related]
9. RNA interference targeting focal adhesion kinase enhances pancreatic adenocarcinoma gemcitabine chemosensitivity.
Duxbury MS; Ito H; Benoit E; Zinner MJ; Ashley SW; Whang EE
Biochem Biophys Res Commun; 2003 Nov; 311(3):786-92. PubMed ID: 14623342
[TBL] [Abstract][Full Text] [Related]
10. Focal adhesion kinase inhibition synergizes with nab-paclitaxel to target pancreatic ductal adenocarcinoma.
Le Large TYS; Bijlsma MF; El Hassouni B; Mantini G; Lagerweij T; Henneman AA; Funel N; Kok B; Pham TV; de Haas R; Morelli L; Knol JC; Piersma SR; Kazemier G; van Laarhoven HWM; Giovannetti E; Jimenez CR
J Exp Clin Cancer Res; 2021 Mar; 40(1):91. PubMed ID: 33750427
[TBL] [Abstract][Full Text] [Related]
11. Enhancing sorafenib-mediated sensitization to gemcitabine in experimental pancreatic cancer through EMAP II.
Awasthi N; Zhang C; Hinz S; Schwarz MA; Schwarz RE
J Exp Clin Cancer Res; 2013 Mar; 32(1):12. PubMed ID: 23497499
[TBL] [Abstract][Full Text] [Related]
12. A small molecule FAK kinase inhibitor, GSK2256098, inhibits growth and survival of pancreatic ductal adenocarcinoma cells.
Zhang J; He DH; Zajac-Kaye M; Hochwald SN
Cell Cycle; 2014; 13(19):3143-9. PubMed ID: 25486573
[TBL] [Abstract][Full Text] [Related]
13. Melatonin overcomes gemcitabine resistance in pancreatic ductal adenocarcinoma by abrogating nuclear factor-κB activation.
Ju HQ; Li H; Tian T; Lu YX; Bai L; Chen LZ; Sheng H; Mo HY; Zeng JB; Deng W; Chiao PJ; Xu RH
J Pineal Res; 2016 Jan; 60(1):27-38. PubMed ID: 26445000
[TBL] [Abstract][Full Text] [Related]
14. Interleukin 35 Expression Correlates With Microvessel Density in Pancreatic Ductal Adenocarcinoma, Recruits Monocytes, and Promotes Growth and Angiogenesis of Xenograft Tumors in Mice.
Huang C; Li Z; Li N; Li Y; Chang A; Zhao T; Wang X; Wang H; Gao S; Yang S; Hao J; Ren H
Gastroenterology; 2018 Feb; 154(3):675-688. PubMed ID: 28989066
[TBL] [Abstract][Full Text] [Related]
15. A PAUF-neutralizing antibody targets both carcinoma and endothelial cells to impede pancreatic tumor progression and metastasis.
Kim SJ; Chang S; Lee Y; Kim NY; Hwang Y; Min HJ; Yoo KS; Park EH; Kim S; Chung YH; Park YW; Koh SS
Biochem Biophys Res Commun; 2014 Nov; 454(1):144-50. PubMed ID: 25450371
[TBL] [Abstract][Full Text] [Related]
16. CYR61/CCN1 Regulates dCK and CTGF and Causes Gemcitabine-resistant Phenotype in Pancreatic Ductal Adenocarcinoma.
Maity G; Ghosh A; Gupta V; Haque I; Sarkar S; Das A; Dhar K; Bhavanasi S; Gunewardena SS; Von Hoff DD; Mallik S; Kambhampati S; Banerjee SK; Banerjee S
Mol Cancer Ther; 2019 Apr; 18(4):788-800. PubMed ID: 30787177
[TBL] [Abstract][Full Text] [Related]
17. Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer.
Venkatasubbarao K; Peterson L; Zhao S; Hill P; Cao L; Zhou Q; Nawrocki ST; Freeman JW
Mol Cancer; 2013 Sep; 12(1):104. PubMed ID: 24025152
[TBL] [Abstract][Full Text] [Related]
18. Impact of completeness of adjuvant gemcitabine, relapse pattern, and subsequent therapy on outcome of patients with resected pancreatic ductal adenocarcinoma - A pooled analysis of CONKO-001, CONKO-005, and CONKO-006 trials.
Kurreck A; Weckwerth J; Modest DP; Striefler JK; Bahra M; Bischoff S; Pelzer U; Oettle H; Kruger S; Riess H; Sinn M
Eur J Cancer; 2021 Jun; 150():250-259. PubMed ID: 33940349
[TBL] [Abstract][Full Text] [Related]
19. Intrinsic chemoresistance to gemcitabine is associated with constitutive and laminin-induced phosphorylation of FAK in pancreatic cancer cell lines.
Huanwen W; Zhiyong L; Xiaohua S; Xinyu R; Kai W; Tonghua L
Mol Cancer; 2009 Dec; 8():125. PubMed ID: 20021699
[TBL] [Abstract][Full Text] [Related]
20. Integration of Bioinformatics Resources Reveals the Therapeutic Benefits of Gemcitabine and Cell Cycle Intervention in SMAD4-Deleted Pancreatic Ductal Adenocarcinoma.
Hsieh YY; Liu TP; Chou CJ; Chen HY; Lee KH; Yang PM
Genes (Basel); 2019 Sep; 10(10):. PubMed ID: 31569425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
